NFKB1 and lung adenocarcinoma: We did not observe any activation of NF-κb in human KRAS-mutant lung adenocarcinomas; in fact, NF-κb activation was significantly lower in KRAS-mutant tumors compared to other Raf/MAPK mutant tumors (Supplementary Table 1).